Pfizer CEO Downplays Health Secretary Nominee's Vaccine Stance
Robert F. Kennedy Jr.'s nomination as Health and Human Services (HHS) secretary has cleared a Senate committee. However, concerns remain over his stance on vaccines.
Pfizer CEO Albert Bourla expressed confidence in Kennedy, stating that his views on vaccines are not as extreme as perceived. Bourla and others have met with Kennedy privately and believe he has moderated his position.
Despite Kennedy's past legal actions against pharmaceutical companies, he has gained support from some, including Sen. Bill Cassidy (R-La.). Cassidy initially had concerns but was swayed after meetings with Kennedy.
Kennedy has publicly acknowledged the importance of childhood vaccines, but has declined to denounce claims of vaccine-autism links, despite overwhelming scientific evidence.
Bourla emphasized Trump's desire to avoid a health crisis, which may have influenced Kennedy's recent tone.
Bourla's close relationship with Trump and upcoming role as PhRMA chairman position him to influence the pharmaceutical industry.
Bourla views the new administration as supportive of the industry, despite concerns about the Biden-era Inflation Reduction Act.
Bourla remains confident in Pfizer's position despite the potential impact of Medicare drug pricing negotiations on two of its drugs.